7Baggers

We provide you with 20 years of free, institutional-grade data for HLVX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of HLVX. Explore the full financial landscape of HLVX stock.

Reported DateCIKTickerType
2025-08-061888012HLVX10-QUrl
2025-05-081888012HLVX10-QUrl
2025-03-281888012HLVX10-KUrl
2024-11-071888012HLVX10-QUrl
2024-08-091888012HLVX10-QUrl
2024-05-091888012HLVX10-QUrl
2024-03-201888012HLVX10-KUrl
2023-11-091888012HLVX10-QUrl
2023-08-141888012HLVX10-QUrl
2023-05-121888012HLVX10-QUrl
2023-03-171888012HLVX10-KUrl
2022-11-101888012HLVX10-QUrl
2022-08-101888012HLVX10-QUrl
2022-06-081888012HLVX10-QUrl
2022-04-061888012HLVXS-1Url

Hillevax Inc
(NASDAQ:HLVX) 

HLVX stock logo

HilleVax, Inc., a clinical-stage biopharmaceutical company, is focused on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts.

Founded: 2020
IPO Price: $17 (Apr 29, 2022)
Sector: TECHNOLOGY
Industry: GENERAL

Share this website to your friends
The information provided in this report about HLVX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.